Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT00651807
PHASE2

A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)

Sponsor: Organon and Co

View on ClinicalTrials.gov

Summary

This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on: * the prostate volume and the urinary complaints; * the urinary flow and the urinary volume in the bladder after voiding; * the progression of the disease; * the sexual function, well-being and urinary complaints-related Quality of Life. In addition the safety and the way the drug is absorbed and excreted by the body will be analyzed.

Official title: Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)

Key Details

Gender

MALE

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2008-03

Completion Date

2008-08

Last Updated

2026-04-08

Healthy Volunteers

No

Interventions

DRUG

etonogestrel

Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks

DRUG

Placebo

Every day one tablet up to 8 weeks

Locations (1)

Instituto Médico Especializado

Buenos Aires, Hidalgo, Argentina